Human Microbiome Therapeutics Market size to grow by USD 732.95 million from 2022 to 2027, North America to account for 41% of market growth, Technavio
NEW YORK, March 6, 2024 /PRNewswire/ -- The human microbiome therapeutics market is expected to grow by USD 732.95 million from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 30.11% during the forecast period, according to Technavio Research. The market is segmented by product (probiotics, prebiotics, medical foods, and prescription drugs), application (gastrointestinal disorders, infectious diseases, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)). North America is estimated to contribute 41% to the growth of the global market during the forecast period. The region's market is stimulated by factors such as strong investments in R&D to develop new drug delivery methods and increased incidence of gastrointestinal disorders, metabolic problems, and immunologic diseases.
This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment.
Key Company:
4D Pharma Plc, BiomX Inc., Eligo Bioscience, ENTEROME SA, Evelo Biosciences Inc., Evogene Ltd., Ferring BV, Finch Therapeutics Group Inc., Flightpath Biosciences, Johnson and Johnson Services Inc., MaaT Pharma, Microbiotica Ltd., OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., Synlogic Inc., Takeda Pharmaceutical Co. Ltd., YSOPIA Bioscience, and Locus Biosciences Inc.
4D Pharma Plc - The company offers human microbiome such as MicroRx.
To gain access to more company profiles available with Technavio,
Segmentation Analysis
The market is segmented by product (probiotics, prebiotics, medical foods, and prescription drugs), application (gastrointestinal disorders, infectious diseases, and others), and geography (North America, Europe, Asia, and Rest of World (ROW)).
The human microbiome therapeutics market share growth by the probiotics segment will be significant during the forecast period. The addition of beneficial bacteria into the body via supplements is an easy way to introduce good bacteria because it contains some health benefits that include removing disease-developing cells, making vitamins, and assisting digestion.
Learn about the contribution of each segment summarized in concise infographics and thorough descriptions.
A robust pipeline in the human microbiome therapeutics market is a key factor driving market growth.
The symbiotic interplay of probiotics, prebiotics, and the complex microbial communities within the human microbiome is integral to gut health. Addressing dysbiosis through microbial therapy, fecal microbiota transplantation (FMT), and advancing microbiome diagnostics amplifies focus on microbial diversity. This holistic approach seeks to harness the potential of the microbiota, shaping innovative treatments in combating chronic illnesses.
- The increasing investments in human microbiome therapeutics are primary trends shaping the market growth.
- The lack of trained professionals in the pharmaceutical industry is a significant challenge in advancing human microbiome therapeutics.
Identify key trends, drivers, and challenges in the market.
Download a sample report to gain access to this information.
Analyst Review
The human microbiome therapeutics market is poised for significant growth as research continues to unveil the intricate relationship between microorganisms residing in the human body and overall health. This burgeoning sector holds promise in addressing a myriad of health conditions, from gastrointestinal disorders to autoimmune diseases, by harnessing the therapeutic potential of the microbiome.
Advancements in microbiome research have elucidated the role of these microscopic organisms in maintaining homeostasis and modulating immune responses. As a result, microbiome-based therapies are emerging as a novel approach to healthcare, offering personalized treatments that target the root cause of various ailments.
One of the key drivers propelling the growth of the human microbiome therapeutics market is the increasing prevalence of chronic diseases worldwide. Conditions such as inflammatory bowel disease (IBD), obesity, and diabetes are closely linked to alterations in the microbiome, creating a demand for innovative treatment options.
Pharmaceutical companies and biotech firms are investing heavily in microbiome-based drug development, recognizing the potential to revolutionize healthcare. Collaborations between academia and industry players are facilitating the translation of microbiome research into clinically viable therapeutics.
Moreover, the growing adoption of precision medicine is driving the demand for tailored microbiome interventions. By leveraging technologies such as metagenomics and microbiome sequencing, healthcare providers can analyze an individual's microbial composition to design personalized treatment regimens.
Regulatory bodies are also actively involved in shaping the human microbiome therapeutics market landscape. Initiatives aimed at streamlining the approval process for microbiome-based drugs are paving the way for more rapid commercialization and accessibility to patients in need.
Despite the promising outlook, challenges persist in the human microbiome therapeutics market, including the need for robust clinical evidence and standardized methodologies for microbiome analysis. Addressing these hurdles will be crucial in unlocking the full potential of microbiome-based therapies and ensuring their widespread adoption in clinical practice.
In conclusion, the human microbiome therapeutics market represents a frontier in healthcare innovation, offering novel solutions for addressing a diverse range of health conditions. With ongoing research, investment, and regulatory support, microbiome-based therapies are poised to transform the treatment landscape, improving patient outcomes and quality of life worldwide.
Download a sample report to gain access to this information.
Related Reports:
The Sepsis Therapeutics Market is estimated to grow by USD 1.42 billion, at a CAGR of 6.98% between 2023 and 2028.
The liver cirrhosis therapeutics market size is estimated to grow by USD 1.94 billion at a CAGR of 5.58% between 2023 and 2028.
ToC:
1 Executive Summary
2 Landscape
3 Sizing
4 Historic Size
5 Five Forces Analysis
6 Segmentations
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Vendor Landscape
11 Vendor Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com
SOURCE Technavio
Share this article